Patents Without Patents:
Regulatory Incentives for Innovation in the Drug Industry
Couldn't attend the event? Check out the video of the event and select speakers' slides below!
In the pharmaceutical industry, patents are the preeminent incentive for innovation in developing new drugs. But patents aren’t the whole story; regulatory agencies also offer different forms of exclusivity—enforced by the agencies themselves—to encourage different forms of innovation in the industry. This panel discussed actual and potential roles for those rewards in the context of developing new drugs, new uses for old drugs, and new ways to make drugs, in both the United States and the European Union. Panelists were:
Benjamin N. Roin, Hieken Assistant Professor in Patent Law, Harvard Law School; Faculty Co-Director, the Petrie-Flom Center
W. Nicholson Price II, Academic Fellow, the Petrie-Flom Center
Timo Minssen, Associate Professor, University of Copenhagen Faculty of Law; Visiting Scholar, the Petrie-Flom Center
Moderator, Aaron Kesselheim, Assistant Professor of Medicine, Harvard Medical School; Director of the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital
Select Speakers' Slide Presentations:
Benjamin N. Roin, "Dormant Therapies"
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
For questions, contact email@example.com or 617-495-2316.
Watch the full event online.